Genomic Health Inc. (NASDAQ:GHDX) shares saw an uptick in trading volume on Monday . 196,296 shares traded hands during mid-day trading, a decline of 10% from the previous session’s volume of 217,430 shares.The stock last traded at $26.86 and had previously closed at $26.48.

A number of analysts have recently commented on GHDX shares. Canaccord Genuity upgraded Genomic Health from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research report on Wednesday, June 1st. Zacks Investment Research cut Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday, August 4th. Leerink Swann reiterated a “buy” rating on shares of Genomic Health in a research report on Thursday, May 26th. Jefferies Group lifted their target price on Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, August 17th. Finally, Bank of America Corp. set a $28.00 target price on Genomic Health and gave the stock a “sell” rating in a research report on Wednesday, August 3rd. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $32.44.

The company’s market cap is $916.35 million. The stock’s 50-day moving average is $28.05 and its 200 day moving average is $26.59.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.18) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.18). The firm earned $81.97 million during the quarter, compared to analysts’ expectations of $81.27 million. During the same period in the previous year, the company earned ($0.29) earnings per share. The business’s quarterly revenue was up 16.1% on a year-over-year basis. On average, equities analysts expect that Genomic Health Inc. will post ($0.47) earnings per share for the current fiscal year.

In other Genomic Health news, insider James J. Vaughn sold 1,997 shares of the company’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $28.00, for a total value of $55,916.00. Following the completion of the transaction, the insider now directly owns 34,076 shares of the company’s stock, valued at approximately $954,128. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Steven Shak sold 5,000 shares of the company’s stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $25.77, for a total transaction of $128,850.00. Following the completion of the transaction, the insider now directly owns 332,107 shares of the company’s stock, valued at $8,558,397.39. The disclosure for this sale can be found here.

Other institutional investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. boosted its position in Genomic Health by 16.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 65,765 shares of the company’s stock worth $2,315,000 after buying an additional 9,308 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Genomic Health by 29.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 60,100 shares of the company’s stock worth $2,116,000 after buying an additional 13,600 shares during the last quarter. Finally, Royce & Associates LLC boosted its position in shares of Genomic Health by 90.0% in the fourth quarter. Royce & Associates LLC now owns 66,500 shares of the company’s stock valued at $2,341,000 after buying an additional 31,500 shares during the last quarter.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.